Table 2.
Characteristics of included studies.
| Study | Country | Modality | Design | Sample size | Follow-up (years) | Subject age | Screening (yes/no) | Quality score** |
|---|---|---|---|---|---|---|---|---|
| Jorgensen 2002 | Denmark | FOBT | RCT | 61,933 | 13 | 45-75 | Yes | 1/5 |
| Lindholm 2008 | Sweden | FOBT | RCT | 68,308 | 9 | 60-64 | Yes | 3/5 |
| Scholefield 2012 | UK | FOBT | RCT | 152,850 | 19.5 | 45-74 | Yes | 2/5 |
| Shaukat 2013 | USA | FOBT | RCT | 46,551 | 30 years | 50-80 | Yes | 2/5 |
| Faivre 2004 | France | FOBT | Quasi experiment | 91,199 | 11 | 45-74 | Yes | 8/9 |
| Lee 2007 | S. Korea | FOBT | Cohort | 42,150 | 13.1 | 40-59 | Yes | 7/9 |
| Malila 2007 | Finland | FOBT | Cohort | 1785 | 19.9 | 50-63 | Yes | 5/9 |
| Libby 2012 | UK | FOBT | Cohort | 759,310 | 3-10 | 50-69 | Yes | 7/9 |
| Newcomb 1992* | USA | FOBT | Case-control | 262 | n/a | Not reported | Yes | 7/9 |
| Hiwatashi 1993 | Japan | FOBT | Case-control | 112 | n/a | Not reported | Yes | 8/9 |
| Selby 1993 | USA | FOBT | Case-control | 1213 | n/a | >50 | Yes | 8/9 |
| Lazovich 1995 | USA | FOBT | Case-control | 693 | n/a | 40-84 | Yes | 9/9 |
| Saito 1995 | Japan | FOBT | Case-control | 770 | n/a | 40-79 | Yes | 9/9 |
| Zappa 1997 | Italy | FOBT | Case-control | 1236 | n/a | >41 | Yes | 6/9 |
| Bertario 1999 | Italy | FOBT | Case-control | 570 | n/a | >40 | Yes | 7/9 |
| Faivre 1999 | France | FOBT | Case-control | 890 | n/a | 45-80 | Yes | 7/9 |
| Scheitel 1999 | USA | FOBT | Case-control | 653 | n/a | >45 | Yes | 9/9 |
| Hoff 2009 | Norway | FS | RCT | 55,736 | 6 | 55-64 | Yes | 3/5 |
| Atkin 2010 | UK | FS | RCT | 170,038 | 11.2 | 55-64 | Yes | 4/5 |
| Segnan 2011 | Italy | FS | RCT | 34,292 | 11.4 | 55-64 | Yes | 3/5 |
| Schoen 2012 | USA | FS | RCT | 154,900 | 11.9 | 55-74 | Yes | 4/5 |
| Thiis-Evensen 1999 | Norway | FS | Quasi Experiment | 799 | 13 | 50-99 | Yes | 5/9 |
| Newcomb 1992* | USA | FS | Case-control | 262 | n/a | Not reported | Yes | 7/9 |
| Muller 1995* | USA | FS | Case-control | 20,889 | n/a | 69 (mean) | No | 8/9 |
| Kahi 2009 | USA | Colonoscopy | Cohort | 715 | 8 | 50-86 | Yes | 8/9 |
| Singh 2010 | Canada | Colonoscopy | Cohort | 54,803 | 5.7 | 50-80 | Yes | 7/9 |
| Jacob 2012 | Canada | Colonoscopy | Cohort | 1,089,998 | 5 to 9 | 50-74 | Yes | 8/9 |
| Manser 2012 | Switzerland | Colonoscopy | Cohort | 22,686 | 6 | 50-80 | Yes | 6/9 |
| Zauber 2012 | USA | Colonoscopy | Cohort | 2602 | 15.8 | 62 (mean) | No | 6/9 |
| Muller 1995* | USA | Colonoscopy | Case-control | 20,889 | n/a | 69 (mean) | No | 8/9 |
| Baxter 2009 | Canada | Colonoscopy | Case-control | 61,752 | n/a | 52-90 | No | 6/9 |
| Baxter 2012 | USA | Colonoscopy | Case-control | 37,099 | n/a | 70-89 | No | 6/9 |
FOBT – fecal occult blood test; FS – flexible sigmoidoscopy
*
Studies evaluating more than 1 modality
**
RCTs rated on a 5-point scale; observational studies rated on a 9-point scale